The Radiation Oncology Residency Training Program at the 650-bed University of North Carolina Hospitals meets all the requirements of the American Board of Radiology (ABR) and is fully accredited by the American Medical Association's Accreditation Council for Graduate Medical Education (ACGME; see also UNC Healthcare's GME site). UNC Hospitals are the teaching hospitals of the UNC School of Medicine, located on the campus of the University of North Carolina at Chapel Hill.
The North Carolina Cancer Hospital is the state's major referral center for patients with cancer and has active oncology subspecialty programs in Radiation Oncology, Medical Oncology, Gynecologic Oncology, Urologic Oncology, Surgical and Breast Oncology, Thoracic Oncology, Head and Neck Cancer, Pediatric Oncology, and Neuro-Oncology. The Cancer Hospital is the clinical face of the UNC Lineberger Comprehensive Cancer Center, one of only 36 National Cancer Institute-designated comprehensive cancer centers in the United States, and nationally recognized for excellence in cutting-edge basic, clinical and translational cancer research.
The Radiation Oncology Residency Training Program at UNC encompasses training in the fundamental principles of oncology, comprehensive cancer management, clinical radiation oncology, radiation treatment techniques, and research experience. The program offers didactic teaching of radiation therapy physics, dosimetry, treatment planning, radiation and cancer biology, and radiation pathology. Teaching is closely integrated with a multidisciplinary approach to state-of-the-art clinical management of cancer patients and investigative clinical research protocols.
The four-year residency program consists of a minimum of 36 months in clinical radiation oncology, electives (or equivalent) in medical oncology, surgical oncology, surgical pathology, diagnostic radiology and nuclear medicine, and radiation physics and dosimetry. In addition, a 6 month research elective supervised by a faculty preceptor is offered in areas such as radiation physics and 2- and 3-D treatment planning, molecular radiation biology, cancer biology, or specialized areas of clinical radiation oncology (IMRT, LDR/HDR brachytherapy, stereotactic radiosurgery, intraoperative radiotherapy, TBI). The Department has an ACGME-approved complement of eight residents (currently six, with one more to be added in 2014 and 2015), with 2 new residents accepted into the program each July.
Clinical training is provided in the standard care of common cancers as well as instruction in the management of unusual and complex oncologic problems. Over 2,200 patients are referred annually to the Department of Radiation Oncology. These include large numbers of patients with breast, gynecological, head and neck, bronchopulmonary, and lymphoreticular malignancies, along with patients with a wide range of other type of cancers. Non-oncologic conditions such as arteriovenous malformations are seen for stereotactic radiosurgery.
As residents advance through their training, they assume increasing responsibility for the evaluation and management of patient referrals, external beam and brachytherapy procedures, care of patients under treatment and follow-up care. Residents work closely with the attending radiation oncologists in all aspects of patient care and are instructed in the new areas of clinical trials, laboratory investigations, and to the development of investigational skills.
Departmental faculty have strong ties to the related disciplines of computer science, biomedical engineering, diagnostic imaging, genetics, nanotechnology, pathology and pharmacology, in addition to providing "in-house" instruction in radiation physics and radiation and cancer biology.
The NC Cancer Hospital, first opened in 2009, houses Radiation Oncology's clinical, physics and computing, educational and administrative programs. (The Radiation and Cancer Biology Division is housed nearby in the Lineberger Comprehensive Cancer Center.) The move to the Cancer Hospital has consolidated all clinical oncology services and professional staff in a single location, and has helped streamline operational efficiency. The move also facilitates unique education and training opportunities for our residents in the form of closer, more flexible interactions with faculty and peers in the other oncology specialties.
The 36,000 square foot Department of Radiation Oncology treats over 1,500 patients per year, and is an integral part of the UNC Lineberger Comprehensive Cancer Center. The Department has active research programs in clinical oncology, radiation and cancer biology, and medical physics, and is an acknowledged world leader in the area of computer-aided radiotherapy treatment planning.
The Department features the following treatment equipment and capabilities: three linear accelerators with MLC and independent jaws; a Calypso® IGRT system; a CT scanner on rails; a dedicated CT scanner for conformal treatment planning; a CyberKnife® stereotactic radiosurgery system; a TomoTherapy® system; a simulator; high and low dose rate brachytherapy equipment; and 3-D treatment planning workstations. These machines permit high energy X-ray, electron beam, and specialized radiation treatments.
A self-shielded, J.L. Shepherd Mark I irradiator is also available for radiation biology research, and serves as a campus-wide core facility for such.
Residents participate in an active brachytherapy program involving over 150 high and low dose rate radiation implant procedures annually for the treatment of gynecological, genitourinary, head and neck, esophagus, lung and other malignancies. Additional prostate brachytherapy experience is available at Rex Hospital, Raleigh, NC, a fully-owned component of UNC Radiation Oncology. A full array of radioactive sources for interstitial and intracavitary radiation therapy is available including iridium-192, iodine-125 and phosphorus-32.
Other specialized treatment programs include intraoperative radiation therapy and total body irradiation for bone marrow transplantation.
Advanced treatment planning systems on computer work stations are used for all types of external beam, interstitial and intracavitary treatment plans that are routinely used in the clinical management of patients. The Department is at the forefront of research and development of sophisticated 3-D imaging and treatment planning for clinical applications, and residents routinely carry out advanced 3-D conformal treatment planning.
Radiation Oncology residents have their own work area equipped with personal computers which are part of the Department's extensive local area network. This network provides ready access to Medline, the Health Sciences Library, UNC Hospitals laboratories and the Tumor Registry, and to the internet.
Didactic teaching courses with lectures once or twice a week are held in radiation physics and dosimetry (annually), and radiation and cancer biology (biennially). Residents participate in teaching, patient care and research in the Department, as well as attend both in-house and multidisciplinary conferences of the UNC Clinical Cancer Program. The in-house conferences include:
- daily morning conferences where residents make case presentations, discuss clinical treatment planning, and review simulations
- weekly chart rounds where current patients receiving radiotherapy are presented
- weekly radiation oncology clinical seminars
- monthly journal clubs with both resident and faculty participation
- monthly morbidity and mortality conferences
- monthly faculty research conferences
- less frequent conferences: Visiting Professor lectures; oncology grand rounds; mock oral boards sessions; In-Training exam review; "best of" medical or scientific conference reports
Regular multidisciplinary conferences are held in conjunction with the Breast Oncology, Gynecologic Oncology, Medical Oncology, Surgical Oncology, Head and Neck Surgery, Pediatric Oncology, Neuro-Oncology and Gastrointestinal Oncology programs. Residents also have an opportunity to attend a variety of oncology-related lectures and symposia elsewhere on the UNC campus.
The Department of Radiation Oncology is actively engaged in clinical investigation programs through national cooperative research groups including the Gynecologic Oncology Group (GOG), Cancer and Acute Leukemia Group B (CALGB), National Surgical Adjuvant Breast Program (NSABP), Radiation Therapy Oncology Group (RTOG), and the Children's Cancer Study Group (CCSG). Intramurally, faculty members are actively engaged in studies of normal tissue toxicity, radiation-drug interactions, and combination therapy with surgery and radiation. Other areas of clinical interest include heath care outcomes research, and human factors/operations research and LEAN management principles with the ultimate goal of improving patient safety (our Department is a national leader in this area).
The Cancer Biology Division has as its emphasis the study of molecular mechanisms of radiation action, new drug discovery and characterization, and basic cancer biology.
The Physics and Computing Division develops and implements state-of-the-art imaging tools that allow radiation oncologists to better understand the various dose delivery systems and to aid in the development of newer techniques of dose delivery. The Division also has an active cancer nanotechnology program.
An additional factor that has major implications for the institutional cancer programs is the University Cancer Research Fund (UCRF). This fund, developed by the state legislature, commits an initial $25M per year, increasing to $50M per year, in support of cancer research efforts at UNC, including the development of clinical excellence in delivery of care to cancer patients and substantial research infrastructure support. A second resource is the North Carolina Translational and Clinical Sciences (NC TraCS) Institute based at UNC, part of a national consortium of medical research institutions that together offer programs and services supporting researchers through all phases of the "bench to bedside" process of translational research. Our Department benefits from both of these programs in terms of our clinical and basic research efforts that, in turn, offer additional training opportunities for our residents.
The Departmental faculty include fourteen ABR-certified radiation oncologists (including those at our satellite facilities), seven ABR-certified radiation physicists, five radiation/cancer biologists, two faculty members devoted largely to education, and joint faculty from the Department of Computer Science. Most are actively involved in the clinical care of oncology patients, teaching and/or research. In addition to mentoring residents, faculty members are also involved in education and training programs for medical students, graduate students, radiation therapists, medical dosimetrists and practicing physicians. They have ongoing research programs, hold leadership roles in national clinical protocol development, and make regular contributions to scientific conferences at the local, regional, national and international levels.
In order to be eligible for our radiation oncology residency training program, an applicant must:
- Be a US citizen or hold a valid US immigration VISA that permits employment in the United States. The UNC Department of Radiation Oncology does not provide sponsorship for any type of immigration VISA.
- Successfully complete all United States Medical Licensing Examination (USMLE) requirements or, if a foreign medical graduate, all Educational Commission for Foreign Medical Graduates (ECFMG) requirements.
- Successfully complete a one year clinical internship in a hospital approved by the ACGME prior to entering the residency training program.
Each year, two new residents meeting all program prerequisites are accepted. Anywhere from 30-40 applicants are selected for personal interviews. Interviews are conducted in groups of 6-8 applicants during the months of November, December and January. Having completed a prior rotation during medical school at the UNC Department of Radiation Oncology does not automatically guarantee an interview for a residency position.
You may obtain additional information by contacting the Program Coordinator:
Ms. Gina Williams
Phone: (919) 445-5206
Current Residents (2013-2014)
|Dr. Gregg Goldin (PGY5)|
|Dr. Noam VanderWalde (PGY5)|
|Dr. Seth Miller (PGY4, Chief Resident)|
|Dr. Michael Eblan (PGY3)|
|Dr. Aaron Falchook (PGY3)|
|Dr. Joseph Caster (PGY2)|
Dr. Nate Sheets
Assistant Professor, UNC/Rex Radiation Oncology, Raleigh, NC
Dr. Dan Higginson
Postdoctoral Research Fellow, Memorial Sloan-Kettering Cancer Center, New York, NY
Dr. Lewis Rosenberg
Cancer Centers of North Carolina, Raleigh, NC
Dr. Randy Kimple
Assistant Professor, Dept. of Human Oncology, University of Wisconsin School of Medicine, Madison, WI
Dr. Steve Harris
Seacoast Cancer Center, Wentworth-Douglass Hospital, Dover, NH
Dr. Jim Apisarnthanarax
Associate Professor, Dept. of Radiation Oncology, University of Washington School of Medicine, Seattle, WA
Dr. Shelileah Ramsey
North Florida Radiation Oncology, Tallahassee, FL
Dr. Janet Horton
Assistant Professor, Dept. of Radiation Oncology, Duke University Medical Center, Durham, NC
Dr. Dan Fried
Spartanburg Radiation Oncology, Spartanburg, SC
- Undergraduate: University of Florida, Gainesville, FL
- Medical School: University of Miami Miller School of Medicine, Miami, FL
- Internship: University of Florida Shands Hospital, Jacksonville, FL
Honors and Awards
- Recipient of an ASTRO Travel Award to attend the 2013 ASTRO Advocacy Day, Washington, DC, April 29-30, 2013
SEER-Medicare population studies; comparative morbidity for prostate cancer; functional imaging and radiation toxicity
(as of 7/15/13)
- Goldin GH, Sheets NC, Meyer AM, Kuo TM, Wu Y, Stürmer T, Godley PA, Carpenter WR, Chen RC. Comparative effectiveness of intensity-modulated radiotherapy and conventional conformal radiotherapy in the treatment of prostate cancer after radical prostatectomy. JAMA Intern Med 173(12):1136-1143, 2013. PMID: 23689844.
- Goldin G. Clinical outcomes of CyberKnife® radiosurgery for early stage lung cancer: low chest wall toxicity rates associated with tracking. (Abstract.) Radiological Society of North American Annual Meeting, Chicago, IL, December, 2012. (Poster presentation.)
- Goldin G, Marks L, Morris, D. Clinical outcomes of Cyberknife radiosurgery for early stage lung cancer: low chest wall toxicity rates associated with tracking. (Abstract.) Annual Multidisciplinary Symposium in Thoracic Oncology, Chicago, IL, September, 2012. (Poster presentation.)
- Sheets NC, Goldin GH, Meyer AM, Wu Y, Chang Y, Stürmer T, Holmes JA, Reeve BB, Godley PA, Carpenter WR, Chen RC. Intensity-modulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer. JAMA 307(15):1611-1620, 2012. PMID: 22511689.
- Goldin, G, Sheets NC, Chen RC. Patterns of intensity modulated radiation therapy (IMRT) use for the definitive and post-operative treatments of prostate cancer, a SEER-Medicare analysis. (Abstract.) American Society for Radiation Oncology Annual Meeting, Miami, FL, October, 2011. (Poster presentation.)
- Sheets NC, Goldin G, Chen RC. Comparative long-term morbidity of intensity-modulated versus conformal radiation therapy (RT) for prostate cancer, a SEER-Medicare analysis. (Abstract.) American Society for Radiation Oncology Annual Meeting, Miami, FL, October, 2011. (Oral presentation.)
- Goldin G, Vargas C, Bridges M. Magnetic resonance spectroscopy and definition of cancer rich targets in the prostate. (Abstract.) American Society for Therapeutic Radiology and Oncology Annual Meeting, Boston, MA, September, 2008. (Poster presentation.)
- Undergraduate: University of Pennsylvania, Philadelphia, PA
- Medical School: University of Maryland School of Medicine, Baltimore, MD
- Internship: Internal Medicine, Mercy Medical Center, Baltimore, MD
Honors and Awards
- Children's Hospital of Los Angeles/USC Keck School of Medicine Summer Oncology Fellowship program, 2006
- Travel award to attend the ASCO/AACR Vail Workshop in “Methods in Clinical Cancer Research”, July, 2012
- Alpha Omega Alpha Postgraduate Award, October, 2012
- Travel award to attend the Joint Hematology/Oncology Alliance for Clinical Trials in Oncology Meeting, and the Cancer and Aging Research Group U13 Conference, November, 2012
- UNC Lineberger Comprehensive Cancer Center Clinical/Translational Developmental Research Award, July, 2013
Geriatric oncology; Health Services research; Head and neck, breast and lung cancers
(as of 10/20/13)
- Vanderwalde NA, Herbert B, Jones E, Muss H. The role of adjuvant radiation treatment in older women with early breast disease. J Geriat Oncol 4(3):262-270, 2013. PMID: 24058388.
- Vanderwalde NA, Fleming M, Weiss J, Chera BS. Treatment of older patients with head and neck cancer: a review. Oncologist 18(5):568-578, 2013. PMID: 23635557.
- Rackoff A, Schenkel S, VanderWalde N. Woman with persistent cough. J Emerg Med 44(1):e71-72, 2013. PMID: 22075537.
- VanderWalde N, Jones E, Kimple R, Moore D, Demore N, Sartor C, Ollila D. Phase II study of pre-excision single dose intraoperative radiation therapy (IORT) for early stage breast cancers: six year update with application of the ASTRO Accelerated Partial Breast Irradiation Consensus Statement criteria. Cancer 119(9):1736-1743, 2013. PMID: 23361892.
- VanderWalde NA, Fried DV, Kostich MV, Schreiber EC, Chera BS. A dosimetric study of the effect of patient positioning on the incidental radiation dose to the larynx for patients treated for head and neck squamous cell carcinoma. (Abstract.) American Society for Radiation Oncology Annual Meeting, Boston, MA, October, 2012. (Poster presentation.)
- VanderWalde NA, Meyer AM, Zullig LL, Tyree SD, Carpenter WR, Weissler MC, Shores CG, Hayes N, Chera BS. Patterns of care in elderly patients with squamous cell carcinoma of the head and neck: a SEER-Medicare Analysis. (Abstract.) American Society of Clinical Oncology Annual Meeting, Chicago, IL, June, 2012. (Poster presentation.)
- Neuner G, Mohiuddin M, VanderWalde N, Goulobeva O, Ha J, Yu C, Regine W. High dose spatially fractionated GRID radiation therapy (SFGRT): a comparison of treatment outcomes with Cerrobend vs. MLC SFGRT. Int J Radiat Oncol Biol Phys 82(5):1642-1649, 2012. PMID: 21531514.
- VanderWalde N, Tyree S, Meyer AM, Carpenter W, Muss H, Shores C, Weissler M, Hayes N, Chera B. SEER-Medicare Analysis of Patterns of Care for Elderly Patients with Squamous Cell Carcinoma of the Head and Neck. (Abstract.) Multidisciplinary Head and Neck Cancer Symposium, Phoenix, AZ, January, 2012. (Poster presentation.)
- VanderWalde NA, Ollila DW, DeMore NK, Moore DT, Kimple RJ, Kuzmiak CM, Pavic D, Sartor CI, Lian J, Jones EL. Local recurrence outcomes in Phase II clinical trial using single dose intraoperative radiotherapy (IORT) before surgical excision of early-stage breast cancer. (Abstract.) American Society for Radiation Oncology Annual Meeting, Miami, FL, October, 2011. (Oral presentation.)
- VanderWalde N, Moore K, Bernheimer J. Paraneoplastic cerebellar degeneration in a patient with unknown primary tumor (Abstract.) American College of Physicians Maryland Region Annual Associates Meeting, Baltimore, Maryland, May, 2010. (Poster presentation.)
- Butturini A, Jacob M, Aguajo J, VanderWalde N, Villablanca J, Jubran R, Epstein A, Marachelian A, Dhall G, Finlay J. High-dose chemotherapy and autologous hematopoietic stem cell transplant in children with recurred medulloblastoma and supratentorial primitive neuro-ectodermal tumors: the impact of prior radiotherapy on post transplant outcome. Cancer 115(13):2956-2963, 2009. PMID: 19402050.
- Undergraduate: University of Florida, Gainesville, FL
- Medical School: University of Florida College of Medicine, Gainesville, FL
- Internship: University of North Carolina Hospitals, Chapel Hill, NC
Honors and Awards
- Genevra Todd and Henry E. Meleney Award for outstanding academic achievement, 2009
- International Medical Mission Service Award to the Dominican Republic, 2009
- ASCO Merit Award; Annual Meeting of the American Society of Clinical Oncology, June, 2013
- ASTRO Scientific Abstract Award; Annual Meeting of the American Society for Radiation Oncology, September, 2013
Image guidance for prostate cancer; regional management of head and neck cancer; patterns of care and utilization of healthcare resources for surgical, medical, and radiation oncology treatment of malignancy
(as of 3/1/14)
- Falchook AD, Zagar TM. A case report of stereotactic radiosurgery in a patient with Ehlers-Danlos syndrome. Rep Pract Oncol Radiother 2013;18(4):241-244. PMID: 24416559.
- Falchook AD, Salloum RG, Hendrix LH, Chen RC. Multiple pathology reviews in prostate cancer diagnosis, prevalence of use in the Medicare population and cost implications. (Abstract.) American Society for Radiation Oncology Annual Meeting, Atlanta, GA, September, 2013. (Oral presentation.)
- Falchook AD, Salloum RG, Hendrix LH, Chen RC. Use of bone scans during initial prostate cancer (CaP) workup, downstream procedures, and associated Medicare costs. (Abstract.) American Society of Clinical Oncology Annual Meeting, Chicago, IL, June, 2013. (Poster presentation.)
- Falchook A, Dagan R, Morris C, Mendenhall W. Elective neck dissection for second primary after previous definitive radiotherapy. Am J Otolaryngology 33(2):199-204, 2012. PMID: 21658804.
- Vargas C, Saito A, Hsi W, Indelicato D, Falchook A, Zengm Q, Oliver K, Keole S, Dempsey J. Cine-magnetic resonance imaging assessment of interfraction motion for prostate cancer patient supine or prone with and without a rectal balloon. Am J Clin Onc 33:11-16, 2010. PMID:19730351.
- Vargas C, Falchook A, Indelicato D, Yeung A, Henderson R, Olivier K, Keole S, Williams C, Li Z, Palta J. Proton therapy for prostate cancer treatment employing online image guidance and an action level threshold. Am J Clin Onc 32:180-186, 2009. PMID: 19307953.
- Yeung A, Vargas C, Falchook A, Louis D, Olivier K, Keole S, Yeung D, Mendenhall N, Li Z. Dose-volume differences for computed tomography and magnetic resonance imaging segmentation and planning for prostate cancer therapy. Int J Radiat Onc Biol Phys 72:1426-1433, 2008. PMID: 18762391
- Vargas C, Wagner M, Mahajan, C, Indelicato D, Fryer A, Falchook A, Horne D, Chellini A, McKenzie C, Lawlor P, Li Z, Lin L, and Keole S. Proton therapy coverage for prostate cancer treatment. Int J Radiat Onc Biol Phys 70:1492-1501, 2008. PMID:18374228.
- Yadava P, Falchook A, Hughes J. Cationic sulfhydryl containing surfactant for siRNA delivery. (Abstract.) American Association of Pharmaceutical Scientists Annual Meeting, San Francisco, CA, May, 2005. (Poster presentation.).
Full-size image: 322.3 KB | View Download
Full-size image: 401.2 KB | View Download
Full-size image: 366.4 KB | View Download
Full-size image: 522.3 KB | View Download
Full-size image: 37.6 KB | View Download
Full-size image: 478.9 KB | View Download